194 related articles for article (PubMed ID: 31079322)
1. Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and rats.
Sepp A; Meno-Tetang G; Weber A; Sanderson A; Schon O; Berges A
J Pharmacokinet Pharmacodyn; 2019 Aug; 46(4):339-359. PubMed ID: 31079322
[TBL] [Abstract][Full Text] [Related]
2. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.
Garg A; Balthasar JP
J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):687-709. PubMed ID: 17636457
[TBL] [Abstract][Full Text] [Related]
3. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
Shah DK; Betts AM
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn.
Chen Y; Balthasar JP
AAPS J; 2012 Dec; 14(4):850-9. PubMed ID: 22956476
[TBL] [Abstract][Full Text] [Related]
5. A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim.
Niederalt C; Kuepfer L; Solodenko J; Eissing T; Siegmund HU; Block M; Willmann S; Lippert J
J Pharmacokinet Pharmacodyn; 2018 Apr; 45(2):235-257. PubMed ID: 29234936
[TBL] [Abstract][Full Text] [Related]
6. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
Gurbaxani B; Dostalek M; Gardner I
Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
[TBL] [Abstract][Full Text] [Related]
7. Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins.
Liu S; Li Y; Li Z; Wu S; Harrold JM; Shah DK
J Pharmacokinet Pharmacodyn; 2024 May; ():. PubMed ID: 38691205
[TBL] [Abstract][Full Text] [Related]
8. Cross-species/cross-modality physiologically based pharmacokinetics for biologics: 89Zr-labelled albumin-binding domain antibody GSK3128349 in humans.
Sepp A; Bergström M; Davies M
MAbs; 2020; 12(1):1832861. PubMed ID: 33073698
[TBL] [Abstract][Full Text] [Related]
9. A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies.
Yuan D; Rode F; Cao Y
AAPS J; 2018 Mar; 20(3):48. PubMed ID: 29541870
[TBL] [Abstract][Full Text] [Related]
10. Model-Based Assessment of the Contribution of Monocytes and Macrophages to the Pharmacokinetics of Monoclonal Antibodies.
Malik PRV; Hamadeh A; Edginton AN
Pharm Res; 2022 Feb; 39(2):239-250. PubMed ID: 35118567
[TBL] [Abstract][Full Text] [Related]
11. Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effects of FcRn Inhibitors in Mice, Rats, and Monkeys.
Li T; Balthasar JP
J Pharm Sci; 2019 Jan; 108(1):701-713. PubMed ID: 30423340
[TBL] [Abstract][Full Text] [Related]
12. Development of a PBPK model for monoclonal antibodies and simulation of human and mice PBPK of a radiolabelled monoclonal antibody.
Heiskanen T; Heiskanen T; Kairemo K
Curr Pharm Des; 2009; 15(9):988-1007. PubMed ID: 19275663
[TBL] [Abstract][Full Text] [Related]
13. Development and Evaluation of a Physiologically Based Pharmacokinetic Model for Predicting the Effects of Anti-FcRn Therapy on the Disposition of Endogenous IgG in Humans.
Li T; Balthasar JP
J Pharm Sci; 2019 Jan; 108(1):714-724. PubMed ID: 30471293
[TBL] [Abstract][Full Text] [Related]
14. A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of K
Maas BM; Cao Y
MAbs; 2018; 10(8):1322-1331. PubMed ID: 30130450
[TBL] [Abstract][Full Text] [Related]
15. Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics.
Li Z; Shah DK
J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):305-318. PubMed ID: 31028591
[TBL] [Abstract][Full Text] [Related]
16. Physiologically based pharmacokinetic (PBPK) model that describes enhanced FcRn-dependent distribution of monoclonal antibodies (mAbs) by pI-engineering in mice.
Naoi S; Yamane M; Nemoto T; Kato M; Saito R; Tachibana T
Drug Metab Pharmacokinet; 2023 Dec; 53():100506. PubMed ID: 38029470
[TBL] [Abstract][Full Text] [Related]
17. Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model.
Li L; Gardner I; Dostalek M; Jamei M
AAPS J; 2014 Sep; 16(5):1097-109. PubMed ID: 25004823
[TBL] [Abstract][Full Text] [Related]
18. Physiologically Based Pharmacokinetic Modeling of Therapeutic Proteins.
Wong H; Chow TW
J Pharm Sci; 2017 Sep; 106(9):2270-2275. PubMed ID: 28392453
[TBL] [Abstract][Full Text] [Related]
19. Physiologically-based pharmacokinetic model for pulmonary disposition of protein therapeutics in humans.
Jagdale P; Sepp A; Shah DK
J Pharmacokinet Pharmacodyn; 2022 Dec; 49(6):607-624. PubMed ID: 36266517
[TBL] [Abstract][Full Text] [Related]
20. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice.
Baxter LT; Zhu H; Mackensen DG; Jain RK
Cancer Res; 1994 Mar; 54(6):1517-28. PubMed ID: 8137258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
